Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4754045
Max Phase: Preclinical
Molecular Formula: C17H19FN6O5S2
Molecular Weight: 470.51
Molecule Type: Unknown
Associated Items:
ID: ALA4754045
Max Phase: Preclinical
Molecular Formula: C17H19FN6O5S2
Molecular Weight: 470.51
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1ccc(Sc2nn([C@H]3C[C@H](O)[C@H](COS(N)(=O)=O)O3)c3ncnc(N)c23)c(F)c1
Standard InChI: InChI=1S/C17H19FN6O5S2/c1-8-2-3-12(9(18)4-8)30-17-14-15(19)21-7-22-16(14)24(23-17)13-5-10(25)11(29-13)6-28-31(20,26)27/h2-4,7,10-11,13,25H,5-6H2,1H3,(H2,19,21,22)(H2,20,26,27)/t10-,11-,13+/m0/s1
Standard InChI Key: GRYCCRMITKNCNZ-GMXVVIOVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 470.51 | Molecular Weight (Monoisotopic): 470.0842 | AlogP: 0.88 | #Rotatable Bonds: 6 |
Polar Surface Area: 168.47 | Molecular Species: NEUTRAL | HBA: 11 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 11 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 11.33 | CX Basic pKa: 3.44 | CX LogP: 1.67 | CX LogD: 1.67 |
Aromatic Rings: 3 | Heavy Atoms: 31 | QED Weighted: 0.47 | Np Likeness Score: -0.58 |
1. Huang SC,Adhikari S,Brownell JE,Calderwood EF,Chouitar J,D'Amore NR,England DB,Foley K,Harrison SJ,LeRoy PJ,Lok D,Lublinsky A,Ma LT,Menon S,Yang Y,Zhang J,Gould AE. (2020) Discovery and optimization of pyrazolopyrimidine sulfamates as ATG7 inhibitors., 28 (19): [PMID:32912429] [10.1016/j.bmc.2020.115681] |
Source(1):